Unknown

Dataset Information

0

In Vivo Evaluation of 68Ga-Labeled NOTA-EGFRvIII Aptamer in EGFRvIII-Positive Glioblastoma Xenografted Model

ABSTRACT:

SUBMITTER: Park J 

PROVIDER: S-EPMC11207964 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
| S-EPMC6280148 | biostudies-literature
Unknown G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells.
| S-EPMC9884419 | biostudies-literature
Unknown Evaluation of Pan-SSTRs Targeted Radioligand [<sup>64</sup>Cu]NOTA-PA1 Using Micro-PET Imaging in Xenografted Mice.
| S-EPMC7153030 | biostudies-literature
Unknown Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.
| S-EPMC12410358 | biostudies-literature
Unknown Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.
| S-EPMC5862541 | biostudies-literature
Unknown Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.
| S-EPMC5029739 | biostudies-literature
Unknown Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.
| S-EPMC7570863 | biostudies-literature
Unknown ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
| S-EPMC6078156 | biostudies-literature
Unknown 68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.
| S-EPMC5223097 | biostudies-literature
Unknown GARNL3 identified as a crucial target for overcoming temozolomide resistance in EGFRvIII-positive glioblastoma.
| S-EPMC11170598 | biostudies-literature